首页> 外文期刊>Clinical ophthalmology >Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy
【24h】

Postoperative subconjunctival bevacizumab injection as an adjunct to 5-fluorouracil in the management of scarring after trabeculectomy

机译:小梁切除术后结膜下贝伐单抗注射作为5-氟尿嘧啶的辅助治疗瘢痕形成

获取原文
           

摘要

Purpose: Scarring after glaucoma filtering surgery remains the most frequent cause for bleb failure. The aim of this study was to assess if the postoperative injection of bevacizumab reduces the number of postoperative subconjunctival 5-fluorouracil (5-FU) injections. Further, the effect of bevacizumab as an adjunct to 5-FU on the intraocular pressure (IOP) outcome, bleb morphology, postoperative medications, and complications was evaluated. Methods: Glaucoma patients (N = 61) who underwent trabeculectomy with mitomycin C were analyzed retrospectively (follow-up period of 25 ± 19 months). Surgery was performed exclusively by one experienced glaucoma specialist using a standardized technique. Patients in group 1 received subconjunctival applications of 5-FU postoperatively. Patients in group 2 received 5-FU and subconjunctival injection of bevacizumab. Results: Group 1 had 6.4 ± 3.3 (0–15) (mean ± standard deviation and range, respectively) 5-FU injections. Group 2 had 4.0 ± 2.8 (0–12) (mean ± standard deviation and range, respectively) 5-FU injections. The added injection of bevacizumab significantly reduced the mean number of 5-FU injections by 2.4 ± 3.08 (P ≤ 0.005). There was no significantly lower IOP in group 2 when compared to group 1. A significant reduction in vascularization and in cork screw vessels could be found in both groups (P < 0.0001, 7 days to last 5-FU), yet there was no difference between the two groups at the last follow-up. Postoperative complications were significantly higher for both groups when more 5-FU injections were applied. (P = 0.008). No significant difference in best corrected visual acuity (P = 0.852) and visual field testing (P = 0.610) between preoperative to last follow-up could be found between the two groups. Conclusion: The postoperative injection of bevacizumab reduced the number of subconjunctival 5-FU injections significantly by 2.4 injections. A significant difference in postoperative IOP reduction, bleb morphology, and postoperative medication was not detected.
机译:目的:青光眼滤过手术后的瘢痕形成仍然是引起泡囊衰竭的最常见原因。这项研究的目的是评估术后贝伐单抗的注射是否减少了结膜下5-氟尿嘧啶(5-FU)注射的次数。此外,评估了贝伐单抗作为5-FU的辅助剂对眼内压(IOP)结局,气泡形态,术后用药和并发症的影响。方法:回顾性分析青光眼患者(N = 61),该患者经丝裂霉素C小梁切除术(随访期为25±19个月)。手术由一名经验丰富的青光眼专家专门采用标准化技术进行。第1组患者术后接受结膜下应用5-FU。第2组患者接受5-FU和结膜下注射贝伐单抗注射。结果:第1组进行了5-FU注射6.4±3.3(0-15)(分别为平均值±标准差和范围)。第2组有4.0±2.8(0-12)(分别为平均±标准偏差和范围)5-FU进样。增加的贝伐单抗注射显着降低了5-FU注射的平均数2.4±3.08(P≤0.005)。与第1组相比,第2组的IOP没有明显降低。两组的血管化和软木螺钉血管均明显减少(P <0.0001,最后5-FU持续7天),但无差异在最后一次随访中两组之间。当使用更多的5-FU注射时,两组的术后并发症明显更高。 (P = 0.008)。两组之间在术前至最后一次随访之间,最佳矫正视力(P = 0.852)和视野测试(P = 0.610)没有显着差异。结论:术后贝伐单抗的注射减少了结膜下5-FU的注射次数,减少了2.4次。没有发现术后眼压降低,气泡形态和术后用药有明显差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号